Nightfood Holdings Enters AI Robotics Partnership with Oncotelic Therapeutics for Pharmaceutical Manufacturing

Nightfood Holdings Inc., doing business as TechForce Robotics, announced a joint development, manufacturing and licensing agreement with Oncotelic Therapeutics to co-develop AI-enhanced, GMP-compliant robotic systems for pharmaceutical manufacturing and laboratory automation. The collaboration combines TechForce’s robotics engineering with Oncotelic’s AI-driven pharmaceutical technologies to target improved efficiency, compliance and scalability in biopharma production.

This partnership represents TechForce Robotics’ strategic expansion into regulated healthcare markets, leveraging Oncotelic CEO Dr. Vuong Trieu’s extensive experience in oncology, drug development and AI-enabled innovation. The joint effort aims to address critical challenges in pharmaceutical manufacturing through automation solutions that can enhance production processes while maintaining strict regulatory compliance standards.

TechForce Robotics, a wholly owned subsidiary of Nightfood Holdings, is an AI-enhanced service-robotics and automation company focused on developing, deploying, and scaling autonomous robotic solutions. The company’s vertically integrated platform combines proprietary robotics technology with real-world operating environments and scalable manufacturing capabilities. While hospitality and foodservice have been TechForce’s initial sectors of entry through its Robotics-as-a-Service platform, this new partnership signals the company’s broader vision to expand into additional verticals requiring similar automation solutions.

The collaboration with Oncotelic Therapeutics represents a significant step in Nightfood Holdings’ long-term strategy to deliver scalable robotics that improve efficiency, reliability, and revenue generation across multiple industries. By entering the biopharma sector, the company is positioning itself at the intersection of robotics, artificial intelligence, and pharmaceutical manufacturing – three fields experiencing rapid technological advancement and growing demand for automation solutions.

For investors seeking additional information about Nightfood Holdings, the company maintains a newsroom at http://ibn.fm/NGTF where updates are regularly posted. The full details of the partnership announcement can be found in the original press release available through TechMediaWire’s distribution network, which specializes in technology-focused corporate communications and maintains comprehensive disclaimers at https://www.TechMediaWire.com/Disclaimer.

The pharmaceutical manufacturing industry faces increasing pressure to improve production efficiency while maintaining rigorous quality standards and regulatory compliance. This partnership addresses these challenges by combining robotics engineering with AI-driven pharmaceutical technologies, potentially creating systems that can adapt to complex manufacturing requirements while reducing human error and increasing throughput. As healthcare markets continue to evolve with technological innovation, such collaborations between robotics companies and biopharma specialists may become increasingly important for maintaining competitive advantages in drug development and production.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Nightfood Holdings Enters AI Robotics Partnership with Oncotelic Therapeutics for Pharmaceutical Manufacturing.

The post Nightfood Holdings Enters AI Robotics Partnership with Oncotelic Therapeutics for Pharmaceutical Manufacturing appeared first on citybuzz.